Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Tetraphase Pharmaceuticals ( TTPH) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate. In addition to specific proprietary factors, Trade-Ideas identified Tetraphase Pharmaceuticals as such a stock due to the following factors:

  • TTPH has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $22.7 million.
  • TTPH has traded 729,053 shares today.
  • TTPH traded in a range 221.7% of the normal price range with a price range of $4.71.
  • TTPH traded above its daily resistance level (quality: 531 days, meaning that the stock is crossing a resistance level set by the last 531 calendar days. The resistance price is defined by the Price - $0.01 at the time of the signal).

Stocks matching the 'Barbarian at the Gate' criteria are worthwhile stocks to watch for a variety of factors including historical back testing and volatility. Trade-Ideas targets these opportunities because the stock is exhibiting an unusual behavior while displaying positive price action. In this case, the stock crossed an important inflection point; namely, 'resistance' while at the same time the range of the stock's movement in price is more than twice its normal size. This large range foreshadows a possible continuation as the stock moves higher.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in TTPH with the Ticky from Trade-Ideas. See the FREE profile for TTPH NOW at Trade-Ideas

If you liked this article you might like

5 Stocks to Trade for Big Breakout Gains

Monsanto, Amazon and Apple: Doug Kass' Views

Tetraphase Pharmaceuticals (TTPH) Weak On High Volume Today

Tetraphase Pharmaceuticals (TTPH): Today's Weak On High Volume Stock

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass